CD274 and neoplasm: The combined biomimetic nanomodulator, light irradiation, and anti-PD-L1 treatment achieved an impressive tumor inhibition rate of 77.29% (P < 0.01 vs. the anti-PD-L1 group), and the number of lung metastatic foci was reduced to 0.67 ± 0.33, significantly lower than in other groups (P < 0.01).